Stockscreener 앱 받기
5.52
3.95%
0.21
시간 외 거래:
5.58
0.06
+1.09%
전일 마감가:
$5.31
열려 있는:
$5.41
하루 거래량:
4.50M
Relative Volume:
1.74
시가총액:
$904.41M
수익:
-
순이익/손실:
$-206.69M
주가수익비율:
-4.0723
EPS:
-1.3555
순현금흐름:
$-186.49M
1주 성능:
+12.42%
1개월 성능:
-6.12%
6개월 성능:
+27.78%
1년 성능:
+161.61%
1일 변동 폭
$5.29
$5.535
1주일 범위
$4.88
$5.565
52주 변동 폭
$1.85
$7.18
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650) 822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.52 | 870.00M | 0 | -206.69M | -186.49M | -1.3555 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Annexon Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Moomoo
Annexon (ANNX) insiders/affiliates report 8.7M-share stake (5.4%) - Stock Titan
ANNX Price Today: Annexon, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
Annexon, Inc.common stock (NQ: ANNX - FinancialContent
Annexon Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference - sharewise.com
Director William Carson Acquires Additional Shares of Annexon In - GuruFocus
Director adds Annexon (ANNX) shares in Rule 10b5-1 plan purchase - Stock Titan
ANNX: Late-stage neuroinflammatory therapies show strong efficacy, with global filings and robust pipeline - TradingView
Annexon (NASDAQ:ANNX) Upgraded by The Goldman Sachs Group to "Hold" Rating - MarketBeat
Goldman Sachs initiates coverage of Annexon (ANNX) with neutral recommendation - MSN
ANNX Initiated Coverage by Goldman Sachs -- Price Target Set at $7.00 - GuruFocus
HC Wainwright Predicts Annexon's Q2 Earnings (NASDAQ:ANNX) - MarketBeat
Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty - Investing.com Canada
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS - Investing News Network
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS - GlobeNewswire Inc.
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
HC Wainwright Has Optimistic View of Annexon FY2030 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN) - The Globe and Mail
Annexon (NASDAQ:ANNX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Annexon Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Annexon, Inc. Stock 12‑Month Price Target Raised to $14.38, Implies 160% Upside - TradingView
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating - Moomoo
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones - Investing News Network
Annexon (NASDAQ: ANNX) trims loss, details GBS and GA drug pipeline - Stock Titan
Annexon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Annexon (NASDAQ: ANNX) trims Q1 2026 loss, targets key GA and GBS milestones - Stock Titan
Annexon targets Q4 data for vision drug in 8M-patient eye disease - Stock Titan
The competitive edge that makes Annexon (ANNX) special (-0.26%) 2026-05-06Momentum Picks - Newser
Annexon to Present at the Bank of America Securities Health Care Conference 2026 - Investing News Network
Annexon to Present at Bank of America Securities Health Care Conference on May 6, 2026 - geneonline.com
EarningsChartMill - ChartMill
Annexon | DEFA14A: Others - Moomoo
Annexon | ARS: Annual Report to Security Holders - Moomoo
ANNX: Late-stage C1q inhibitors show strong efficacy in GBS and GA, with pivotal data due in 2026 - TradingView
Annexon (NASDAQ: ANNX) proxy asks approval to boost share authorization and elect directors - Stock Titan
Annexon stock rises after director purchases shares - MSN
Annexon presents four studies on Guillain-Barre syndrome disease burden and targeted therapies - Traders Union
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential - Yahoo Finance
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):